Data_Sheet_1_Development and acceptability of a decision aid for anxiety disorder considering discontinuation of benzodiazepine anxiolytic.PDF

AimWe aimed to develop a decision aid (DA) for individuals with anxiety disorders who consider tapering benzodiazepine (BZD) anxiolytics, and if tapering, tapering BZD anxiolytics with or without cognitive behavioral therapy (CBT) for anxiety. We also assessed its acceptability among stakeholders.MethodsFirst, we conducted a literature review regarding anxiety disorders to determine treatment options. We cited the results of the systematic review and meta-analysis, which we conducted previously, to describe the related outcomes of two options: tapering BZD anxiolytics with CBT and tapering BZD anxiolytics without CBT. Second, we developed a DA prototype in accordance with the International Patient Decision Aid Standards. We carried out a mixed methods survey to assess the acceptability among stakeholders including those with anxiety disorders and healthcare providers.ResultsOur DA provided information such as explanation of anxiety disorders, options of tapering or not tapering BZD anxiolytics (if tapering, the options of tapering BZD anxiolytics with or without CBT) for anxiety disorder, benefits and risks of each option, and a worksheet for value clarification. For patients (n = 21), the DA appeared to be acceptable language (86%), adequate information (81%), and well-balanced presentation (86%). The developed DA was also acceptable for healthcare providers (n = 10).ConclusionWe successfully created a DA for individuals with anxiety disorders who consider tapering BZD anxiolytics, which was acceptable for both patients and healthcare providers. Our DA was designed to assist patients and healthcare providers to involve decision-making about whether to taper BZD anxiolytics or not.

本研究旨在为考虑逐步减少苯二氮䓬类药物（BZD）抗焦虑药的患者开发决策辅助工具（DA），若患者选择逐步减少，则评估其在接受或未接受认知行为疗法（CBT）的情况下逐步减少BZD抗焦虑药的治疗方案。此外，我们还评估了该方案在利益相关者中的可接受度。研究方法：首先，我们对焦虑障碍的文献进行了综述，以确定治疗方案。我们引用了先前进行的系统评价和荟萃分析的结果，描述了两种方案的相关结果：在接受CBT的情况下逐步减少BZD抗焦虑药和在不接受CBT的情况下逐步减少BZD抗焦虑药。其次，我们根据国际患者决策辅助工具标准开发了DA原型。我们进行了一项混合方法调查，以评估包括焦虑障碍患者和医疗保健提供者在内的利益相关者的可接受度。研究结果：我们的DA提供了关于焦虑障碍的解释、逐步减少或未减少BZD抗焦虑药（若选择逐步减少，包括接受或未接受CBT的逐步减少BZD抗焦虑药）的选项、每个选项的益处和风险，以及价值澄清工作表。对于患者（n=21），DA在可接受的语言（86%）、充足的信息（81%）和平衡的展示（86%）方面似乎得到了认可。开发的DA也适用于医疗保健提供者（n=10）。结论：我们成功地为考虑逐步减少BZD抗焦虑药的焦虑障碍患者开发了一个DA，该工具对病人和医疗保健提供者均具有可接受性。我们的DA旨在协助患者和医疗保健提供者在是否逐步减少BZD抗焦虑药方面做出决策。